Míriam Arumí

Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial

Aleix Prat, Cristina Saura, Tomás Pascual et al. · The Lancet Oncology · 2019 · 201 citations

Medicine, Oncology, Pharmacology +16

MET expression and copy number heterogeneity in nonsquamous non-small cell lung cancer (nsNSCLC)

David Casadevall, Javier Gimeno, Sergi Clavé et al. · Oncotarget · 2015 · 58 citations · Full text

Medicine, Molecular Genetics, Oncology +17

Patritumab deruxtecan in untreated hormone receptor-positive/HER2-negative early breast cancer: final results from part A of the window-of-opportunity SOLTI TOT-HER3 pre-operative study

Mafalda Oliveira, Claudette Falato, Juan Miguel Cejalvo et al. · Annals of Oncology · 2023 · 41 citations · Full text

Medicine, Oncology, Pharmacology +17

Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early response

Fara Brasó‐Maristany, J.M. Ferrero-Cafiero, Claudette Falato et al. · Nature Communications · 2024 · 23 citations · Full text

Medicine, Oncology, Pharmacology +16

Patritumab deruxtecan in leptomeningeal metastatic disease of solid tumors: the phase 2 TUXEDO-3 trial

Matthias Preusser, J. Garde, Juan Garcia et al. · Nature Medicine · 2025 · 17 citations · Full text

Medicine, Oncology, Pharmacology +15